Latest news with #ThomasWakim
Business Insider
09-05-2025
- Business
- Business Insider
Neuren Pharmaceuticals Limited (NURPF) Receives a Buy from Bell Potter
Bell Potter analyst Thomas Wakim maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report) today and set a price target of A$20.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -6.9% and a 40.00% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals , and Opthea . In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a A$27.90 price target. The company has a one-year high of $15.43 and a one-year low of $5.41. Currently, Neuren Pharmaceuticals Limited has an average volume of 1,176.
Business Insider
01-05-2025
- Business
- Business Insider
Bell Potter Sticks to Its Buy Rating for Genetic Signatures Ltd. (GSS)
In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Genetic Signatures Ltd. (GSS – Research Report), with a price target of A$0.75. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -13.4% and a 23.08% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Opthea , Clinuvel Pharmaceuticals , and CSL. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genetic Signatures Ltd. with a A$1.05 average price target. Based on Genetic Signatures Ltd.'s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$8.5 million and a GAAP net loss of A$15.2 million. In comparison, last year the company earned a revenue of A$3.6 million and had a GAAP net loss of A$10.47 million
Business Insider
30-04-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)
Bell Potter analyst Thomas Wakim maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) today and set a price target of A$2.30. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -13.4% and a 23.08% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Opthea , Clinuvel Pharmaceuticals , and CSL. Currently, the analyst consensus on PYC Therapeutics Limited is a Strong Buy with an average price target of A$3.35.
